1. Home
  2. ASMB vs RVPH Comparison

ASMB vs RVPH Comparison

Compare ASMB & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • RVPH
  • Stock Information
  • Founded
  • ASMB 2005
  • RVPH 2006
  • Country
  • ASMB United States
  • RVPH United States
  • Employees
  • ASMB N/A
  • RVPH N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • RVPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • ASMB Health Care
  • RVPH Health Care
  • Exchange
  • ASMB Nasdaq
  • RVPH Nasdaq
  • Market Cap
  • ASMB 92.1M
  • RVPH 88.0M
  • IPO Year
  • ASMB 2010
  • RVPH N/A
  • Fundamental
  • Price
  • ASMB $13.42
  • RVPH $2.09
  • Analyst Decision
  • ASMB Buy
  • RVPH Strong Buy
  • Analyst Count
  • ASMB 2
  • RVPH 5
  • Target Price
  • ASMB $35.00
  • RVPH $11.40
  • AVG Volume (30 Days)
  • ASMB 22.6K
  • RVPH 1.8M
  • Earning Date
  • ASMB 03-27-2025
  • RVPH 11-14-2024
  • Dividend Yield
  • ASMB N/A
  • RVPH N/A
  • EPS Growth
  • ASMB N/A
  • RVPH N/A
  • EPS
  • ASMB N/A
  • RVPH N/A
  • Revenue
  • ASMB $28,326,000.00
  • RVPH N/A
  • Revenue This Year
  • ASMB $282.16
  • RVPH N/A
  • Revenue Next Year
  • ASMB N/A
  • RVPH N/A
  • P/E Ratio
  • ASMB N/A
  • RVPH N/A
  • Revenue Growth
  • ASMB N/A
  • RVPH N/A
  • 52 Week Low
  • ASMB $9.84
  • RVPH $0.60
  • 52 Week High
  • ASMB $19.93
  • RVPH $4.83
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 40.25
  • RVPH 60.41
  • Support Level
  • ASMB $13.60
  • RVPH $1.78
  • Resistance Level
  • ASMB $14.25
  • RVPH $2.15
  • Average True Range (ATR)
  • ASMB 0.58
  • RVPH 0.15
  • MACD
  • ASMB -0.05
  • RVPH 0.02
  • Stochastic Oscillator
  • ASMB 5.93
  • RVPH 88.30

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: